Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 356

1.

Cancer-Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery.

Vaughan HJ, Green JJ, Tzeng SY.

Adv Mater. 2019 Jun 20:e1901081. doi: 10.1002/adma.201901081. [Epub ahead of print] Review.

PMID:
31222852
2.

Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo.

Kozielski KL, Ruiz-Valls A, Tzeng SY, Guerrero-Cázares H, Rui Y, Li Y, Vaughan HJ, Gionet-Gonzales M, Vantucci C, Kim J, Schiapparelli P, Al-Kharboosh R, Quiñones-Hinojosa A, Green JJ.

Biomaterials. 2019 Jul;209:79-87. doi: 10.1016/j.biomaterials.2019.04.020. Epub 2019 Apr 12.

PMID:
31026613
3.

Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival.

Lopez-Bertoni H, Kozielski KL, Rui Y, Lal B, Vaughan H, Wilson DR, Mihelson N, Eberhart CG, Laterra J, Green JJ.

Nano Lett. 2018 Jul 11;18(7):4086-4094. doi: 10.1021/acs.nanolett.8b00390. Epub 2018 Jun 28.

4.

Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments.

Karlsson J, Vaughan HJ, Green JJ.

Annu Rev Chem Biomol Eng. 2018 Jun 7;9:105-127. doi: 10.1146/annurev-chembioeng-060817-084055. Epub 2018 Mar 26. Review.

5.

Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma.

Zamboni CG, Kozielski KL, Vaughan HJ, Nakata MM, Kim J, Higgins LJ, Pomper MG, Green JJ.

J Control Release. 2017 Oct 10;263:18-28. doi: 10.1016/j.jconrel.2017.03.384. Epub 2017 Mar 27.

6.

Attending to physical, mental and spiritual needs.

Vaughan H.

Nurs N Z. 2015 Nov;21(10):34. No abstract available.

PMID:
26717635
7.

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer.

Mitchell PL, Quinn MA, Grant PT, Allen DG, Jobling TW, White SC, Zhao A, Karanikas V, Vaughan H, Pietersz G, McKenzie IF, Gargosky SE, Loveland BE.

J Immunother Cancer. 2014 Jun 18;2:16. doi: 10.1186/2051-1426-2-16. eCollection 2014.

8.

Supporting our senior citizens in their own homes.

Vaughan H.

Aust Nurs J. 2013 Jun;20(11):52. No abstract available.

PMID:
23862345
9.
10.

Antibody responses to glycolipid-borne carbohydrates require CD4+ T cells but not CD1 or NKT cells.

Christiansen D, Vaughan HA, Milland J, Dodge N, Mouhtouris E, Smyth MJ, Godfrey DI, Sandrin MS.

Immunol Cell Biol. 2011 May;89(4):502-10. doi: 10.1038/icb.2010.166. Epub 2011 Feb 1. Erratum in: Immunol Cell Biol. 2011 May;89(4):574. Miland, Julie [corrected to Milland, Julie].

PMID:
21283109
11.

Tuning the intramolecular charge transfer emission from deep blue to green in ambipolar systems based on dibenzothiophene S,S-dioxide by manipulation of conjugation and strength of the electron donor units.

Moss KC, Bourdakos KN, Bhalla V, Kamtekar KT, Bryce MR, Fox MA, Vaughan HL, Dias FB, Monkman AP.

J Org Chem. 2010 Oct 15;75(20):6771-81. doi: 10.1021/jo100898a.

PMID:
20860348
12.

The interplay of conformation and photophysical properties in deep-blue fluorescent oligomers.

Li H, Batsanov AS, Moss KC, Vaughan HL, Dias FB, Kamtekar KT, Bryce MR, Monkman AP.

Chem Commun (Camb). 2010 Jul 14;46(26):4812-4. doi: 10.1039/c0cc00211a. Epub 2010 May 25.

PMID:
20502782
13.

Ocular angiostrongyliasis--first case report from Jamaica.

Mattis A, Mowatt L, Lue A, Lindo J, Vaughan H.

West Indian Med J. 2009 Sep;58(4):383-5.

PMID:
20099782
14.

Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation.

Christiansen D, Milland J, Mouhtouris E, Vaughan H, Pellicci DG, McConville MJ, Godfrey DI, Sandrin MS.

PLoS Biol. 2008 Jul 15;6(7):e172. doi: 10.1371/journal.pbio.0060172.

15.

On the angular dependence of the optical polarization anisotropy in ladder-type polymers.

Vaughan HL, Monkman AP, Pålsson LO, Nehls BS, Farrell T, Scherf U.

J Chem Phys. 2008 Jan 28;128(4):044709. doi: 10.1063/1.2822273.

PMID:
18247983
16.

External quality assessment for the molecular detection of Hepatitis C virus.

Chalker VJ, Rossouw A, Mee Z, Patel P, Vaughan H, James VL.

J Clin Virol. 2007 Jun;39(2):141-4. Epub 2007 May 17.

PMID:
17500030
17.
18.

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.

Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77.

19.

Stability of lyophilised specimens for the molecular detection of viral DNA/RNA.

Vaughan H, Chalker VJ, Mee Z, Rossouw A, James V.

J Clin Virol. 2006 Feb;35(2):135-40. Epub 2005 Jul 18.

PMID:
16024290
20.

External quality assessment for detection of Chlamydia trachomatis.

Chalker VJ, Vaughan H, Patel P, Rossouw A, Seyedzadeh H, Gerrard K, James VL.

J Clin Microbiol. 2005 Mar;43(3):1341-7.

21.
22.

Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1.

Vaughan HA, Svobodova S, Macgregor D, Sturrock S, Jungbluth AA, Browning J, Davis ID, Parente P, Chen YT, Stockert E, St Clair F, Old LJ, Cebon J.

Clin Cancer Res. 2004 Dec 15;10(24):8396-404.

23.

The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning.

Vaughan HA, St Clair F, Scanlan MJ, Chen YT, Maraskovsky E, Sizeland A, Old LJ, Cebon J.

Cancer Immun. 2004 Jul 16;4:5.

24.

Phylogeography and molecular evolution of dengue 2 in the Caribbean basin, 1981-2000.

Foster JE, Bennett SN, Carrington CV, Vaughan H, McMillan WO.

Virology. 2004 Jun 20;324(1):48-59.

25.

Dengue viruses in the Caribbean. Twenty years of dengue virus isolates from the Caribbean Epidemiology Centre.

Campione-Piccardo J, Ruben M, Vaughan H, Morris-Glasgow V.

West Indian Med J. 2003 Sep;52(3):191-8.

PMID:
14649098
26.

Characterization of HIV type 1 clades in the Caribbean using pol gene sequences.

Vaughan HE, Cane P, Pillay D, Tedder RS.

AIDS Res Hum Retroviruses. 2003 Oct;19(10):929-32.

PMID:
14601595
27.

Establishing the Canadian Community Monitoring Network.

Whitelaw G, Vaughan H, Craig B, Atkinson D.

Environ Monit Assess. 2003 Oct-Nov;88(1-3):409-18.

PMID:
14570426
28.

Linking ecological science to decision-making: delivering environmental monitoring information as societal feedback.

Vaughan H, Whitelaw G, Craig B, Stewart C.

Environ Monit Assess. 2003 Oct-Nov;88(1-3):399-408.

PMID:
14570425
29.

Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.

Cebon J, Jäger E, Shackleton MJ, Gibbs P, Davis ID, Hopkins W, Gibbs S, Chen Q, Karbach J, Jackson H, MacGregor DP, Sturrock S, Vaughan H, Maraskovsky E, Neumann A, Hoffman E, Sherman ML, Knuth A.

Cancer Immun. 2003 Jul 16;3:7.

30.

Molecular evolution and phylogeny of dengue type 4 virus in the Caribbean.

Foster JE, Bennett SN, Vaughan H, Vorndam V, McMillan WO, Carrington CV.

Virology. 2003 Feb 1;306(1):126-34.

31.

Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies.

Wang Y, Han KJ, Pang XW, Vaughan HA, Qu W, Dong XY, Peng JR, Zhao HT, Rui JA, Leng XS, Cebon J, Burgess AW, Chen WF.

J Immunol. 2002 Jul 15;169(2):1102-9.

32.

Expression of the MAGE-1 gene in human hepatocellular carcinomas.

Chen H, Cai S, Wang Y, Zhao H, Peng J, Pang X, Zhu J, Cong X, Rui J, Leng X, Du R, Wang Y, Vaughan H, Cebon J, Burgess AW, Chen W.

Chin Med J (Engl). 2000 Dec;113(12):1112-8.

PMID:
11776148
33.

Spatiotemporal maturation of the central and lateral N1 components to tones.

Gomes H, Dunn M, Ritter W, Kurtzberg D, Brattson A, Kreuzer JA, Vaughan HG Jr.

Brain Res Dev Brain Res. 2001 Aug 23;129(2):147-55.

PMID:
11506859
34.

Efficacy and safety of orally/sublingually, intranasally, and intraperitoneally administered recombinant murine interferon in the treatment of murine encephalomyocarditis virus.

Sonnenfeld G, Tovey M, Schellekens H, Kinney KS, Belay T, Morton DS, Austin CE, Reitman M, Fong TA, Vaughan HS.

J Interferon Cytokine Res. 2001 Jul;21(7):539-45.

PMID:
11506749
35.

Visual activation of frontal cortex: segregation from occipital activity.

Saron CD, Schroeder CE, Foxe JJ, Vaughan HG Jr.

Brain Res Cogn Brain Res. 2001 Aug;12(1):75-88.

PMID:
11489611
36.

Monitoring long-term ecological changes through the Ecological Monitoring and Assessment Network: science-based and policy relevant.

Vaughan H, Brydges T, Fenech A, Lumb A.

Environ Monit Assess. 2001 Feb-Mar;67(1-2):3-28.

PMID:
11339704
37.

Mismatch negativity in children and adults, and effects of an attended task.

Gomes H, Molholm S, Ritter W, Kurtzberg D, Cowan N, Vaughan HG Jr.

Psychophysiology. 2000 Nov;37(6):807-16.

PMID:
11117461
38.

MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma.

Gibbs P, Hutchins AM, Dorian KT, Vaughan HA, Davis ID, Silvapulle M, Cebon JS.

Melanoma Res. 2000 Jun;10(3):259-64.

PMID:
10890380
39.

The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan.

Vaughan HA, Ho DW, Karanikas V, Sandrin MS, McKenzie IF, Pietersz GA.

Vaccine. 2000 Aug 1;18(28):3297-309.

PMID:
10869775
40.

Two cognitive systems simultaneously prepared for opposite events.

Ritter W, Sussman E, Deacon D, Cowan N, Vaughan HG Jr.

Psychophysiology. 1999 Nov;36(6):835-8.

PMID:
10554596
41.

Molecular diagnosis of dengue by reverse transcriptase-polymerase chain reaction.

Vaughan HE, George A, Morris-Glasgow V, Campione-Piccardo J.

West Indian Med J. 1999 Sep;48(3):118-22.

PMID:
10555455
42.

Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan-human MUC1 conjugates.

Vaughan HA, Ho DW, Karanikas VA, Ong CS, Hwang LA, Pearson JM, McKenzie IF, Pietersz GA.

Vaccine. 1999 Jun 4;17(20-21):2740-52.

PMID:
10418926
43.

An investigation of the auditory streaming effect using event-related brain potentials.

Sussman E, Ritter W, Vaughan HG Jr.

Psychophysiology. 1999 Jan;36(1):22-34.

PMID:
10098377
44.

Predictability of stimulus deviance and the mismatch negativity.

Sussman E, Ritter W, Vaughan HG Jr.

Neuroreport. 1998 Dec 21;9(18):4167-70.

PMID:
9926868
45.

Electrophysiological evidence of developmental changes in the duration of auditory sensory memory.

Gomes H, Sussman E, Ritter W, Kurtzberg D, Cowan N, Vaughan HG Jr.

Dev Psychol. 1999 Jan;35(1):294-302.

PMID:
9923483
46.

Reactivation of a dormant representation of an auditory stimulus feature.

Ritter W, Gomes H, Cowan N, Sussman E, Vaughan HG Jr.

J Cogn Neurosci. 1998 Sep;10(5):605-14.

PMID:
9802993
47.

Feature conjunctions and auditory sensory memory.

Sussman E, Gomes H, Nousak JM, Ritter W, Vaughan HG Jr.

Brain Res. 1998 May 18;793(1-2):95-102.

PMID:
9630541
48.

Attention affects the organization of auditory input associated with the mismatch negativity system.

Sussman E, Ritter W, Vaughan HG Jr.

Brain Res. 1998 Apr 6;789(1):130-8.

PMID:
9602095
49.

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.

Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, Jamieson G, Pietersz G, Tait B, Broadbent R, Thynne G, McKenzie IF.

J Clin Invest. 1997 Dec 1;100(11):2783-92.

50.

Lexical processing of visually and auditorily presented nouns and verbs: evidence from reaction time and N400 priming data.

Gomes H, Ritter W, Tartter VC, Vaughan HG Jr, Rosen JJ.

Brain Res Cogn Brain Res. 1997 Oct;6(2):121-34.

PMID:
9450605

Supplemental Content

Loading ...
Support Center